Literature DB >> 7018667

Isolation of a nontoxic lipid A fraction containing tumor regression activity.

K Takayama, E Ribi, J L Cantrell.   

Abstract

Galanos-type endotoxin obtained from the heptose-less mutant of Salmonella typhimurium was converted to Lipid A by two cycles of treatment with sodium acetate, pH 4.5, at 100 degrees and separated on a DEAE-cellulose column into several fractions (Fractions III to VII). Tumor regression studies with strain 2 guinea pigs and syngeneic line 10 hepatocellular carcinoma showed that all fractions were effective when combined with trehalose dimycolates and an additional tumor regression factor (previously designated ACP) and incorporated into oil droplets (78 to 100% cures). A low polar fraction (Fraction IV) was relatively nontoxic [the medium lethal dose for 11-day-old chick embryos inoculated i.v. (CELD50) was more than 10 micrograms] and nonpyrogenic [the dose estimated to give a fever index (area under fever curve) of 40 sq cm in rabbits when 1 hr and 1 degrees are plotted as 1 (FI40) was 5 micrograms] as compared to the unfractionated Lipid A (CELD50 of 0.0546 micrograms; FI40 of 0.046 micrograms). All other fractions were toxic and pyrogenic and caused severe endotoxic shocks when combined with N-acetylmuramyl-L-seryl-D-isoglutamine and injected i.v. into guinea pigs. Fraction IV plus N-acetylmuramyl-L-seryl-D-isoglutamine did not cause endotoxic shock. The phosphate content of Fraction IV was about one-half of that detected in the toxic fractions.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7018667

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Involvement of gamma interferon in antibody enhancement by adjuvants.

Authors:  M J Odean; C M Frane; M Van derVieren; M A Tomai; A G Johnson
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

2.  Monophosphoryl Lipid A: A Novel Agent for Inducing Pharmacologic Myocardial Preconditioning.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

3.  Induction of antitumor activities in spleen cells from mice and rats activated with lipopolysaccharide immobilized on beads.

Authors:  H Abe; T Tani; J Shibata; M Kodama
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Heterogeneity of lipid A: comparison of lipid A types from different gram-negative bacteria.

Authors:  I Mattsby-Baltzer; P Gemski; C R Alving
Journal:  J Bacteriol       Date:  1984-09       Impact factor: 3.490

Review 5.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

6.  Influence of fine structure of lipid A on Limulus amebocyte lysate clotting and toxic activities.

Authors:  K Takayama; N Qureshi; C R Raetz; E Ribi; J Peterson; J L Cantrell; F C Pearson; J Wiggins; A G Johnson
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

7.  Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A.

Authors:  J E Domer; L G Human; G B Andersen; J A Rudbach; G L Asherson
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

8.  Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine.

Authors:  Kawther K Ahmed; Sean M Geary; Aliasger K Salem
Journal:  J Pharm Sci       Date:  2016-01-30       Impact factor: 3.534

9.  Enhancement of macrophage-mediated tumor cell killing by bacterial outer membrane proteins (porins).

Authors:  J B Weinberg; E Ribi; R W Wheat
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

Review 10.  Understanding how lipopolysaccharide impacts CD4 T-cell immunity.

Authors:  Jeremy P McAleer; Anthony T Vella
Journal:  Crit Rev Immunol       Date:  2008       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.